Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes

Maria Creignou, Elsa Bernard, Michael Crowther, Anna Tranberg, Elisabeth Ejerblad, Lars Nilsson, Hege Garelius, Petar Antunovic, Bengt Erik Holger Rasmussen, Fryderyk Lorenz, Gabriele Todisco, Gunilla Walldin, Teresa Mortera-Blanco, Monika Jansson, Magnus Tobiasson, Gustaf Edgren, Martin Jadersten, Elli Papaemmanuil, Eva Hellström-Lindberg

Blood (2022) 140 (Supplement 1): 6968–6970.

https://doi.org/10.1182/blood-2022-155811

Published: 2022

Journal Articles

Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138782

Published: 2020

Journal Articles

Constitutional SAMD9L Mutations Cause Familial Myelodisplastic Syndrome with Monosomy 7 and Stable Revertant Mosaicism

Blood (2017) 130 (Supplement 1): 1672.

https://doi.org/10.1182/blood.V130.Suppl_1.1672.1672

Published: 2017

Journal Articles

Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms

Blood (2017) 129 (16): 2266–2279.

https://doi.org/10.1182/blood-2016-10-743302

Published: 2017

Includes: Supplemental data

Journal Articles

Cytopenia, Predisposition to Myelodysplastic Syndrome, Immunodeficiency, and Neurological Disease Caused By Gain-of-Function SAMD9L Mutations Is Frequently Ameliorated By Hematopoietic Revertant Mosaicism

Blood (2016) 128 (22): 4299.

https://doi.org/10.1182/blood.V128.22.4299.4299

Published: 2016

Journal Articles

A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy

Marie Lindgren, MD, Jan Samuelsson, MD PhD, Lars Nilsson, MD PhD, Håvar Knutsen, MD, Waleed Ghanima, MDPhD, Maria Åström, MD PhD, Elisabeth Ejerblad, MD, Anna Hugosson, MD, Peter L. Johansson, MD PhD, Björn Andréasson, MD PhD

Blood (2014) 124 (21): 1861.

https://doi.org/10.1182/blood.V124.21.1861.1861

Published: 2014

Journal Articles

Characterisation of the Stem and Progenitor Cell Hierarchy in Patients with CMML

Onima Chowdhury, MD PhD, Petter S Woll, PhD, Una Kjällquist, PhD, Helen Doolittle, MD, Rikard Erlandsson, PhD, Kristina Anderson, MD PhD, Ingunn Dybedal, MD PhD, Adam Mead, MDPhD, Sally-Ann Clark, PhD, Mette S. Holm, MD PhD, Peter Hokland, MD DMSc, Lars Nilsson, MD PhD, Sten Linnarsson, PhD, Eva Hellstrom-Lindberg, MD PhD, Sten Eirik W Jacobsen, MD PhD

Blood (2014) 124 (21): 1896.

https://doi.org/10.1182/blood.V124.21.1896.1896

Published: 2014

Journal Articles

Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells

Blood (2013) 122 (21): 4195.

https://doi.org/10.1182/blood.V122.21.4195.4195

Published: 2013

Journal Articles

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Magnus Tobiasson, MD, Lena Brandefors, MD, Ingunn Dybedal, MD, PhD, Hege Garelius, MD, Michael Grövdal, MD, PhD, Inge Hoegh Dufva, MD, PhD, Lars Kjeldsen, MD, PhD, Lars Nilsson, MD, PhD, Astrid Olsnes Kittang, MD, PhD, Anna Porwit, MD, PhD, Leonie Saft, MD, Mette Skov Holm, MD, PhD, Lars Möllgård, MD, Phd, Eva Hellström-Lindberg

Blood (2011) 118 (21): 3798.

https://doi.org/10.1182/blood.V118.21.3798.3798

Published: 2011

Journal Articles

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Blood (2011) 118 (14): 3765–3776.

https://doi.org/10.1182/blood-2011-01-330126

Published: 2011

Includes: Supplemental data

Journal Articles

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities.

Lars Möllgård, Lars Nilsson, Lars Kjeldsen, Ingunn Dybedal, Inge Hogh Dufva, Hege Garelius, Jan Maxwell Norgaard, Olle Linder, Elisabeth Ejerblad, Jan Astermark, Eva Hellström-Lindberg

Blood (2009) 114 (22): 115.

https://doi.org/10.1182/blood.V114.22.115.115

Published: 2009

Journal Articles

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Anna Porwit, Peter Hokland, Eva Hellström-Lindberg

Blood (2008) 112 (11): 223.

https://doi.org/10.1182/blood.V112.11.223.223

Published: 2008

Journal Articles

Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.

Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Peter Hokland, Anna Porwit, Eva Hellström-Lindberg

Blood (2007) 110 (11): 818.

https://doi.org/10.1182/blood.V110.11.818.818

Published: 2007

Journal Articles

The molecular signature of MDS stem cells supports a stem-cell origin of 5q− myelodysplastic syndromes

Lars Nilsson, Patrik Edén, Eleonor Olsson, Robert Månsson, Ingbritt Åstrand-Grundström, Bodil Strömbeck, Kim Theilgaard-Mönch, Kristina Anderson, Robert Hast, Eva Hellström-Lindberg, Jan Samuelsson, Gösta Bergh, Claus Nerlov, Bertil Johansson, Mikael Sigvardsson, Åke Borg, Sten Eirik W. Jacobsen

Blood (2007) 110 (8): 3005–3014.

https://doi.org/10.1182/blood-2007-03-079368

Published: 2007

Includes: Supplemental data

Journal Articles

Lenalidomide Up-Regulates SPARC and Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome Patients with 5q Deletion.

Andrea Pellagatti, Martin Jädersten, Ann-Mari Forsblom, Helen Cattan, Birger Christensson, Emma K. Emanuelsson, Mats Merup, Lars Nilsson, Jan Samuelsson, Birgitta Sander, James S. Wainscoat, Jacqueline Boultwood, Eva Hellström-Lindberg

Blood (2006) 108 (11): 855.

https://doi.org/10.1182/blood.V108.11.855.855

Published: 2006

Journal Articles

A Distinct Molecular Signature of Purified Cancer Stem Cells: Evidence for a Hematopoietic Stem Cell Origin of the 5q- Syndrome.

Lars Nilsson, MD, PhD, Patrik Edén, PhD, Eleonor Olsson, Robert Månsson, Ingbritt Åstrand-Grundström, Bodil Strömbeck, Ramin Tehranchi, MD, PhD, Kim Theilgaard-Mönch, Robert Hast, MD, PhD, Eva Hellström-Lindberg, MD, PhD, Jan Samuelsson, MD, PhD, Gösta Bergh, MD, PhD, Bertil Johansson, MD, PhD, Mikael Sigvardsson, PhD, Åke Borg, PhD, Sten-Eirik W. Jacobsen, MD, PhD

Blood (2005) 106 (11): 4382.

https://doi.org/10.1182/blood.V106.11.4382.4382

Published: 2005

Journal Articles

Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes

Ramin Tehranchi, Rosangela Invernizzi, Alf Grandien, Boris Zhivotovsky, Bengt Fadeel, Ann-Mari Forsblom, Erica Travaglino, Jan Samuelsson, Robert Hast, Lars Nilsson, Mario Cazzola, Rolf Wibom, Eva Hellström-Lindberg

Blood (2005) 106 (1): 247–253.

https://doi.org/10.1182/blood-2004-12-4649

Published: 2005

Journal Articles

Erythropoiesis Is Highly Stimulated in CD34 + Cells in Low-Risk Myelodysplastic Syndromes (MDS) with an Improper Mitochondrial Function.

Ramin Tehranchi, MD, Rosangela Invernizzi, MD, PhD, Boris Zhivotovsky, PhD, Bengt Fadeel, MD, PhD, Ann-Mari Forsblom, Erica Travaglino, Jan Samuelsson, MD, Robert Hast, MD, PhD, Lars Nilsson, MD, PhD, Rolf Wibom, PhD, Alf Grandien, PhD, Mario Cazzola, MD, PhD, Eva Hellstrom-Lindberg, MD, PhD

Blood (2004) 104 (11): 473.

https://doi.org/10.1182/blood.V104.11.473.473

Published: 2004

Journal Articles

A Phase II Trial of Pegylated Interferon α-2b in Polycythemia Vera and Essential Thrombocythemia. Clinical Responses, Effects on PRV-1 Expression and Impact on Quality of Life.

Jan Samuelsson, MD, PhD, Hans Hasselbalch, Oystein Bruserud, Heike Pahl, Mats Merup, Olle Linder, Yvonne Brandberg, Poul Gram-Hansen, Magnus Bjorkholm, Waleed Ghanima, Claes Malm, Berit Markevarn, Torben Mourits-Andersen, Peter Johansson, Lars Nilsson, Gunnar Birgegard

Blood (2004) 104 (11): 1518.

https://doi.org/10.1182/blood.V104.11.1518.1518

Published: 2004

Journal Articles

Involvement and functional impairment of the CD34 + CD38 − Thy-1 + hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8

Lars Nilsson, Ingbritt Åstrand-Grundström, Kristina Anderson, Ingrid Arvidsson, Peter Hokland, David Bryder, Lars Kjeldsen, Bertil Johansson, Eva Hellström-Lindberg, Robert Hast, Sten Eirik W. Jacobsen

Blood (2002) 100 (1): 259–267.

https://doi.org/10.1182/blood-2001-12-0188

Published: 2002

NARROW

Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes

Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B

Constitutional SAMD9L Mutations Cause Familial Myelodisplastic Syndrome with Monosomy 7 and Stable Revertant Mosaicism

Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms

Cytopenia, Predisposition to Myelodysplastic Syndrome, Immunodeficiency, and Neurological Disease Caused By Gain-of-Function SAMD9L Mutations Is Frequently Ameliorated By Hematopoietic Revertant Mosaicism

A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy

Characterisation of the Stem and Progenitor Cell Hierarchy in Patients with CMML

Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities.

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.

The molecular signature of MDS stem cells supports a stem-cell origin of 5q− myelodysplastic syndromes

Lenalidomide Up-Regulates SPARC and Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome Patients with 5q Deletion.

A Distinct Molecular Signature of Purified Cancer Stem Cells: Evidence for a Hematopoietic Stem Cell Origin of the 5q- Syndrome.

Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes

Erythropoiesis Is Highly Stimulated in CD34 + Cells in Low-Risk Myelodysplastic Syndromes (MDS) with an Improper Mitochondrial Function.

A Phase II Trial of Pegylated Interferon α-2b in Polycythemia Vera and Essential Thrombocythemia. Clinical Responses, Effects on PRV-1 Expression and Impact on Quality of Life.

Involvement and functional impairment of the CD34 + CD38 − Thy-1 + hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only